Actos Lawsuit Advice | Actos Cancer

Wrongful Death Lawsuit Alleges Actos Cancer

Staff Writer | January 6th, 2012

Actos cancer was responsible for a New York resident’s wrongful death, according to the Actos lawyers who are representing his widow in federal court. A plaintiff sought legal advice after the Actos bladder cancer death of her husband on December 22, 2009.

Widow files action in Actos cancer death

The Actos lawyers reviewing her case found that the plaintiff’s husband had been prescribed Actos by his physician for the treatment of type II diabetes in 2001 and that he had been taking the medication for years prior to being diagnosed with urethelial cancer, a recognized type of Actos cancer. According to the FDA, the risk of developing Actos cancer is increased in patients who take the drug for longer than twelve months, as in this case.

Bladder cancer victims seek Actos lawsuit advice

The lawsuit was filed on December 20, 2011. Her Actos lawyers allege that Takeda Pharmaceuticals and Eli Lilly failed to warn consumers of the risk of developing Actos cancer and actively concealed their knowledge that Actos can cause urethelial cancer from consumers and the medical community.

Accordingly, the Actos cancer complaint includes claims for fraud, fraudulent concealment, negligence, and strict products liability, among other causes of action.

Actos cancer an established concern

Patients seeking Actos lawsuit advice will discover that numerous medical studies have established the link between use of the popular type II diabetes medication and Actos cancer, particularly when the drug is used for longer than twelve months.

Even prior to the FDA’s approval of the drug in 1999, a two-year carcinogenicity study was conducted on male and female rats, and drug-induced tumors were observed in male rats receiving doses of Actos equivalent to clinical doses taken by humans.

A later clinical trial demonstrated that patients receiving Actos developed bladder cancer at a rate 2.5 times above those receiving a placebo. Widespread reports of Actos cancer moved the FDA to announce in September of 2011 that it will embark on a longitudinal study to further assess the risk of using Actos over a long-term period.

Many individuals injured by Actos cancer have sought Actos lawsuit advice from an experienced attorney to assess their eligibility for seeking compensation in court.